India, July 21 -- NKGen Biotech, Inc. (NKGN), a clinical-stage developer of natural killer cell therapies, announced Monday that the FDA has approved an Intermediate-Size Expanded Access Program IND for its troculeucel candidate in a range of neurodegenerative disorders.
Beyond its ongoing Phase 2a Alzheimer's trial, this open-label, nonrandomized protocol will permit treatment of up to 20 patients with early-stage Alzheimer's, Parkinson's disease, ALS, multiple system atrophy, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration, multiple sclerosis, and Lewy body dementia-conditions with few or no effective therapies.
NKGN is currently trading at $0.24, down $0.025 or 9.43 percent on the OTC Markets.
For co...